$5 Million is being donated to research into medical MDMA
There has been several studies conducted on the legitimacy of using MDMA, also known as Molly, to treat those suffering with post-traumatic stress disorder (PTSD). Some of these trials have been promising, and it is very possible that using MDMA to treat PTSD could be extremely helpful for patients. Currently, MDMA is classified as a Schedule 1 substance under the Controlled Substances Act, which states that the drug is highly illegal in North America. Consequentially, the illegality of the substance makes funding and allowance to conduct studies and trials on MDMA difficult.
In an effort to get MDMA approved legally by the U.S Food and Drug Administration, American soap company, Dr. Bronner’s, has agreed to donate $5 million to Multidisciplinary Association for Psychedelic Studies also known as MAPS. Dr Bronner’s donation will be spread out in $1 million increments over five years.
CEO David Bronner stated recently,
“There is tremendous suffering and pain that the responsible integration of MDMA for treatment-resistant PTSD will alleviate and heal. To help inspire our allies to close the funding gap, my family has pledged $1 million a year for five years – $5 million total – by far our largest gift to an NGO partner to date.
In part, we were inspired by the incredible example of Ashawna Hailey, former MAPS Board member, who gave MAPS $5 million when she died in 2011.”
The drug has recently been granted permission to enter Phase 3 of a clinical trial; meaning that testing of drug on patients to assess efficacy, effectiveness and safety is allowed.
Many promising studies have been conducted on an array of psychedelic substances like psilocybin, iboga, and ayahuasca to treat a variety of different ailments, including depression, anxiety, addiction, PTSD, and many other psychological disorders. We will see in the coming years what these clinical trials have in store for the future of MDMA.